article thumbnail

Edible Cholera vaccine made of powdered rice proves safe in phase 1 human trials

Scienmag

A new vaccine to protect against deadly cholera has been made by grinding up genetically modified grains of rice. The first human trial has shown no obvious side effects and a good immune response. Study points towards role of gut microbiome in vaccine effectiveness Credit: Image by Dr. Hiroshi Kiyono, CC BY 4.0

article thumbnail

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

XTalks

The Burnaby, BC-based company developed the oral DNA-based vaccine using its proprietary bacTRL Gene Therapy Platform, which uses genetically modified bifidobacteria as carriers of genetic vaccine elements on a DNA plasmid. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vaccine shows promise against herpes virus

Scienmag

New study demonstrates candidate’s potential to generate antibodies, limit viral shedding Credit: Craig Chandler, University of Nebraska-Lincoln A genetically edited form of a herpes simplex virus — rewired to keep it from taking refuge in the nervous system and eluding an immune response — has outperformed a leading vaccine candidate (..)

article thumbnail

Mutations leading to omicron variant did not enable virus to fully escape immune system

The Pharma Data

That’s because the mutations that led to the variant’s emergence aren’t found in the regions of the virus that stimulates one type of cellular immune response, says an international research team from Johns Hopkins Medicine, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and ImmunoScape, a U.S.-Singapore

article thumbnail

AZ expands phase 3 trials of COVID-19 vaccine frontrunner into US

pharmaphorum

The UK pharma said that the trial will recruit up to 30,000 adults aged 18 years or over to assess the safety, efficacy and immune response. The trial is assessing efficacy and safety of the vaccine in all participants, and local and systemic reactions and immune responses will be assessed in 3,000 participants.

article thumbnail

Study finds structural changes in the SARS-CoV-2 Alpha and Beta variants

Scienmag

Changes to the ‘spike’ protein explain Alpha’s faster spread, and how the Beta variant evades immune responses, suggesting the need for a booster with an updated vaccine Credit: Bing Chen, PhD, Boston Children’s Hospital New SARS-CoV-2 variants are spreading rapidly, and there are fears that current COVID-19 vaccines won’t (..)

article thumbnail

World AIDS Day 2023: New and Promising Treatments for HIV/AIDS

XTalks

This candidate, derived from a person’s own genetically modified cells, aims to restore the Gag-specific CD4+ T cell response in those receiving antiretroviral therapy. In November 2023, Hookipa Pharma Inc., Notably, it significantly reduced viral load and clinical illness compared to a placebo.